DYNE THERAPEUTICS
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives.
DYNE THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.dyne-tx.com
Total Employee:
11+
Status:
Active
Total Funding:
333 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Ribonexus
Ribonexus is a biotech specialized in the development of new therapies to combat cancer disease.
Capital Rx
Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.
Cisiv
Cisiv is a developer of technology solutions for pharmaceutical companies.
Endeavor BioMedicines
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
HAYA Therapeutics
HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.
LUCA Science
LUCA Science develops innovative treatments intended for mitochondrial and related diseases.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Orasis Pharmaceuticals
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
PolyActiva
PolyActiva develops products that enable drug release from medical devices.
Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Sydnexis
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Syndesi Therapeutics
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Logos Capital
Logos Capital investment in Series B - Dyne Therapeutics
Wellington Management
Wellington Management investment in Series B - Dyne Therapeutics
Vida Ventures
Vida Ventures investment in Series B - Dyne Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - Dyne Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Dyne Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Dyne Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Dyne Therapeutics
MPM Capital
MPM Capital investment in Series B - Dyne Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Dyne Therapeutics
MPM Capital
MPM Capital investment in Series A - Dyne Therapeutics
Key Employee Changes
Date | New article |
---|---|
2020-01-13 | Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy |
Official Site Inspections
http://www.dyne-tx.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.53 K
- Host name: 187.128.203.35.bc.googleusercontent.com
- IP address: 35.203.128.187
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043